Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 11/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CCL2 | P13500 | 1/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16793236 | 0.80 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2BRD4MAPK1 | |
| SCHEMBL18918396 | 0.78 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2BRD4ADORA3 | |
| SCHEMBL28510085 | 0.77 | KDM4E (0.48) | KDM4EALDH1A1SMN1; SMN2BRD4MAPK1 | |
| SCHEMBL14378230 | 0.68 | DPP4 (0.48) | ALDH1A1PTGS2 | |
| SCHEMBL11575773 | 0.68 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2BRD4MAPK1 | |
| SCHEMBL16793353 | 0.67 | ALDH1A1 (1.00) | KDM4EALDH1A1SMN1; SMN2BRD4MAPK1 | |
| SCHEMBL369523 | 0.64 | BRD4 (0.46) | KDM4EALDH1A1SMN1; SMN2BRD4 | |
| SCHEMBL11101039 | 0.64 | ALDH1A1 (0.40) | KDM4EALDH1A1SMN1; SMN2BRD4MAPK1 | |
| SCHEMBL9458564 | 0.63 | ALDH1A1 (0.49) | KDM4EALDH1A1SMN1; SMN2BRD4PTGS2 | |
| SCHEMBL776398 | 0.62 | CA1 (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885ALDH1A1 3316/4885SMN1; SMN2 4410/4885 |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885ALDH1A1 3316/4885SMN1; SMN2 4410/4885 |
| US-10023592-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | KDM4E 137/4885ALDH1A1 3316/4885SMN1; SMN2 4410/4885 |
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | KDM4E 137/4885ALDH1A1 3316/4885SMN1; SMN2 4410/4885 |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885ALDH1A1 3316/4885SMN1; SMN2 4410/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | KDM4E 137/4885ALDH1A1 3316/4885SMN1; SMN2 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.